In a small pilot study of patients with advanced pancreatic cancer, early access to medical cannabis shows promise in the ...

SAN FRANCISCO -- Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease ...

Immuneering Corporation has reported updated Phase 2a data showing atebimetinib plus modified gemcitabine/nab-paclitaxel ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of ...

NP-G2-044 (Prilukae), a novel oral fascin inhibitor, has earned orphan drug designation (ODD) from the FDA for the treatment ...

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of ...

Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...